glp 1 telehealth Claya launches Platform for GLP-1 Medications GLP-1 Plus Core High Dose

The Master Complaint claims failure to provide sufficient warnings about the increased risk, breach of warranties, fraudulent concealment, unfair trade practices, strict product liability, misrepresentation, negligent design and on and on and on

Back Sheridan, C (14 April 2025) 'Not just obesity: GLP-1 receptor agonists advance on addiction', Nature Biotechnology , 43, 455-47.Back Sims, EK, Carr, ALJ, Oram, RA, et al (15 July 2022) '100 years of insulin: celebrating the past, present and future of diabetes therapy', Nature Medicine , 27/7, 1154-64

Critics of this study suggest that a comparison with metformin, previously shown to improve asthma outcomes, would be necessary to further reveal the efficacy of GLP-1 receptor agonist treatment in this setting, as well as some statistical/methodical issues [47]

And the following year, in 2009, two more research reports were published suggesting that exendin-4 was having positive effects in models of Parkinsons ( Click here and here to read those reports)